Table 1.
Baseline characteristics of three statin groups.
| Variables | Pitavastatin (N = 1312, 15.7%) |
Atorvastatin (N = 3034, 36.4%) |
Rosuvastatin (N = 3991, 47.9%) |
p-Value |
|---|---|---|---|---|
| Follow up (days) | 468.31 ± 446.18 | 558.30 ± 666.85 | 648.30 ± 796.06 | <0.001 |
| NODM | 167 (12.7%) | 555 (18.3%) | 864 (21.6%) | <0.001 |
| Gender (male) | 728 (55.5%) | 1546 (51.0%) | 2236 (56.0%) | <0.001 |
| Age | 60.42 ± 12.44 | 61.53 ± 13.54 | 58.21 ± 13.45 | <0.001 |
| BMI | 25.71 ± 4.18 | 24.75 ± 4.08 | 25.11 ± 4.38 | 0.017 |
| Comorbidities | ||||
| CAD | 551 (42.0%) | 798 (26.3%) | 931 (23.3%) | <0.001 |
| Hypertension | 796 (60.7%) | 1416 (46.7%) | 1864 (46.7%) | <0.001 |
| COPD | 195 (14.9%) | 363 (12.0%) | 419 (10.5%) | <0.001 |
| CKD | 29 (2.2%) | 154 (5.1%) | 90 (2.3%) | <0.001 |
| Cancer | 82 (6.2%) | 313 (10.3%) | 266 (6.7%) | <0.001 |
| Ischemic stroke | 160 (12.2%) | 508 (16.7%) | 736 (18.4%) | <0.001 |
| Hemorrhagic stroke | 24 (1.8%) | 76 (2.5%) | 71 (1.8%) | 0.086 |
| Heart failure | 100 (7.6%) | 213 (7.0%) | 256 (6.4%) | 0.279 |
| Biochemistry | ||||
| LDL (mg/dL) | 131.52 ± 28.51 | 122.94 ± 37.57 | 141.30 ± 45.86 | <0.001 |
| TC (mg/dL) | 202.91 ± 35.03 | 198.53 ± 46.67 | 218.96 ± 54.14 | <0.001 |
| TG (mg/dL) | 138.95 ± 74.01 | 138.80 ± 84.14 | 164.14 ± 133.90 | <0.001 |
| Creatinine (mg/dL) | 0.89 ± 0.27 | 1.03 ± 0.98 | 0.94 ± 0.64 | <0.001 |
| ALT (U/L) | 23.59 ± 16.43 | 23.64 ± 20.52 | 25.78 ± 19.71 | <0.001 |
| Uric Acid (mg/dL) | 6.07 ± 1.56 | 6.05 ± 1.66 | 6.13 ± 1.79 | 0.376 |
| FG (mg/dL) | 99.94 ± 15.74 | 99.27 ± 17.31 | 99.57 ± 17.98 | 0.581 |
| HbA1c (%) | 6.05 ± 0.98 | 6.08 ± 1.17 | 6.09 ± 1.23 | 0.872 |
ALT: alanine aminotransferase; BMI: body mass index; CAD: coronary artery disease; CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease; FG: fasting glucose; HbA1c: glycated hemoglobin; LDL: low-density lipoprotein; N: number of patients; NODM: new-onset diabetes mellitus; TC: total cholesterol; TG: triglyceride.